Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WDB coco CoTSE:7079 -1.15%72 EBIT per Share is 円401.13 as of Mar. 2026. GuruFocus rates TSE:7079 with a GF Score™ of 72/100 and a GF Value™ of 円3,464.83 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 524 Healthcare Providers & Services companies, WDB coco Co ranks worse than 73.85% on this metric.
WDB coco Co's EBIT per Share for the
six
months ended in Mar. 2026 was 円233.23.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円401.13.
During the past 12 months, the average EBIT per Share Growth Rate of WDB coco Co was -26.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -4.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 12.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for WDB coco Co's EBIT per Share or its related term are showing as below:
TSE:7079'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -4.1 Med: 23.25 Max: 34.1
Current: -4.1
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of WDB coco Co was 34.10% per year. The lowest was -4.10% per year. And the median was 23.25% per year.
TSE:7079's 3-Year EBIT Growth Rate is ranked worse than 73.85% of 524
companies
in the Healthcare Providers & Services industry
Industry Median: 11.95
vs TSE:7079: -4.10
WDB coco Co's EBIT for the
six
months ended in Mar. 2026 was 円561 Mil.
WDB coco Co (TSE:7079) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
WDB coco Co EBIT per Share Related Terms
WDB coco Co EBIT per Share Historical Data
* Premium members only.
The historical data trend for WDB coco Co's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円401.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WDB coco Co (TSE:7079) has a EBIT per Share of 円401.13 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on WDB coco Co and its competitors. According to the industry distribution chart, WDB coco Co ranks #387 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 73.9%.
Is WDB coco Co's EBIT per Share too high?
WDB coco Co's current EBIT per Share is 円401.13. Based on the distribution chart, WDB coco Co ranks #387 out of 524 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, WDB coco Co has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WDB coco Co's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, WDB coco Co ranks #387 out of 524 companies for EBIT per Share. This places WDB coco Co in the lower half of its industry. The industry median EBIT per Share is 11.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.95, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on WDB coco Co and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WDB coco Co's current EBIT per Share is 円401.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WDB coco Co stock overvalued right now?
Based on GuruFocus' analysis, WDB coco Co (TSE:7079) is currently considered Modestly Undervalued. The stock's GF Value™ is 円3,464.83, compared to a current price of 円2,580.00 — trading 25.5% below its estimated fair value. The current EBIT per Share is 円401.13. WDB coco Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For WDB coco Co (TSE:7079), the current EBIT per Share is 円401.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WDB coco Co (TSE:7079) Overvalued in 2026?
Based on GuruFocus' analysis, WDB coco Co stock appears to be undervalued.
The current stock price of 円2,580.00 is trading 25.5% below its estimated GF Value™ of 円3,464.83.
GuruFocus considers WDB coco Co to be Modestly Undervalued.
Key valuation signals for TSE:7079:
EBIT per Share: 円401.13
GF Value™: 円3,464.83 vs. price of 円2,580.00 (25.5% below fair value)
No single metric tells the full story. See the TSE:7079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WDB coco Co Ltd is a provider of safety information management for the development of pharmaceuticals and medical devices. Its services include business related to safety information management, preparation of materials related to regulatory application, QC-related work, PMS facility contract support related work, clinical research support/monitoring, and temporary staffing. The company provides Contract Research Organization services for all new drug developments, such as monitoring, safety information, data management, and statistical analysis. It provides support for the development of generic drugs, such as bioequivalence studies and biosimilars, clinical research, and physician-led clinical trials.
72GF Score
Get the complete analysis for TSE:7079
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7079 has been successfully added to your 
